FindTrial
Sign In

Use of artificial intelligence techniques to evaluate the presence of diseases other than cancer in women with breast, ovarian, uterine and cervical cancer, being treated at Tata Memorial Hospitals

Occurrence & frequency of comorbidities in Womenâ??s cancers (Breast, Cervical, Ovarian & Uterus) in India at Tata Memorial Hospitals.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/06/034365
Enrollment
100000
Registered
2021-06-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

Intervention1: This is not applicable. Observation study: This is not applicable. Observation study

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: a. Presence of diagnosis of included conditions (Breast, Cervical, Ovarian & Uterine cancer) b. Patient of Tata Memorial Hospitals within Greater Mumbai registered between January 2015 till December 2019. c. Availability of electronic health records. d. Patients with incomplete health records will also be included in the study and will be quantified in the output. e. Patients treated with both curative and palliative intent will be included in the study.

Exclusion criteria

Exclusion criteria: No exclusion criteria

Design outcomes

Primary

MeasureTime frame
A detailed descriptive analysis including the quantum of missing data, of the occurrence, frequency and temporal patterns of comorbidities in patients with major womenâ??s cancers.Timepoint: 1 YEAR—

Secondary

MeasureTime frame
A well developed and usable Common Data Model for this cohort of patients.Timepoint: 1 yr—

Countries

India

Contacts

Public ContactYogesh Kembhavi

Tata Memorial Centre

sudeepgupta04@yahoo.com02224177201

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026